Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

1(11%)

Results Posted

57%(4 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

11%

Ph phase_3

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

1(12.5%)

Phase 3Large-scale testing

4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(7)

Terminated(1)

Detailed Status

Completed7

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (37.5%)

Phase 21 (12.5%)

Phase 34 (50.0%)

Trials by Status

terminated111%

completed778%

recruiting111%

Recent Activity

1 active trials

Showing 5 of 9

recruitingphase_2

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

NCT02991469

completed

An Observational Study on Sarilumab-exposed Pregnancies

NCT03378219

terminatedphase_3

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

NCT03600818

completedphase_3

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

NCT02293902

completedphase_3

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT02991469Phase 2

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Recruiting

NCT03378219

An Observational Study on Sarilumab-exposed Pregnancies

Completed

NCT03600818Phase 3

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Terminated

NCT02293902Phase 3

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Completed

NCT01768572Phase 3

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Completed

NCT02121210Phase 3

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Completed

NCT02017639Phase 1

Sarilumab Effect on the Pharmacokinetics of Simvastatin

Completed

NCT02404558Phase 1

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Completed

NCT01850680Phase 1

Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis